CRDL

Cardiol Therapeutics Inc. [CRDL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CRDL Stock Summary

In the News

CRDL Financial details

Company Rating
-
Market Cap
121.11M
Income
-28.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
-3.2
Forward P/E
-
PEG
0.81
P/S
-
P/B
2.57
P/C
-
P/FCF
-3.26
Quick Ratio
5.08
Current Ratio
5.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
-32.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-23.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
-65%
ROC
-0.87%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.511-2.17
52W High
-
52W Low
-
RSI
59
Rel Volume
0.67
Avg Volume
400.76K
Volume
268.68K
Perf Week
5.9%
Perf Month
15.53%
Perf Quarter
12.96%
Perf Half Y
18.22%
-
-
-
-
Beta
0.752
-
-
Volatility
0.04%, 0.1%
Prev Close
3.04%
Price
1.525
Change
3.39%

Something similar

Top by Market Cap
3V64.DE
BRH.DE
FB2A.DE
MSFT
TL0.DE
Same Sector
HUM
QIA.DE
0722.HK
BIVI
RHE
Same Price Range
FCP.LS
DHY
TMQ.TO
EVE.SW
601880.SS
Similar Market Cap
PHPM.L
XNET
1891.HK
GIF.L
NCZ

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 400.76K
  • Market Capitalization 121.11M
  • Employee 22
  • CEO Mr. David G. Elsley MBA
  • Headquarters Oakville,ON,CA
  • IPO Date 2019-01-15
  • Website https://www.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.